Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04981821 · ClinicalTrials.gov registry record · NA
A Randomized Trial of a Mobile Health Exercise Intervention for Older Adults With Myeloid Neoplasms
A NA study of Cancer and Myeloid Neoplasm, sponsored by University of Rochester.
- Recruiting
- Registry status
- NA
- Development phase
- 170
- Enrollment target
- 1
- Study location
NCT04981821: Recruiting NA study of Cancer and Myeloid Neoplasm, sponsored by University of Rochester.
NCT04981821 is a NA study of Cancer and Myeloid Neoplasm that is actively recruiting participants, run by University of Rochester. The registered enrollment target is 170 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04981821, a NA study of Cancer and Myeloid Neoplasm, is actively recruiting participants, sponsored by University of Rochester.
- RECRUITING
- Registry status
- NA
- Development phase
- 170 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 2 randomized controlled trial (RCT) to assess the preliminary efficacy of the a mobile health exercise intervention (GO-EXCAP) versus a chemotherapy education control in 100 older patients with MN receiving outpatient chemotherapy on physical function and patient-reported outcomes (fatigue, mood, and quality of life). We will also explore the effect of the intervention on TNFα and related cytokine gene promoter methylation and their gene and protein expression.
Primary Outcome
Changes in physical function measured using the Short Physical Performance Battery (SPPB) which an objective physical assessment evaluating lower extremity physical function (score ranges from 0-12; higher score indicates better physical function). It is comprised of 3 components: a four-meter walk, repeated chair stands and a balance test (the score for each component ranges from 0-4).
Conditions Studied
Interventions
- BEHAVIORAL GO-EXCAP Mobile App
- BEHAVIORAL Behavioral Placebo Control
Study Locations (1)
New York
- University of Rochester Medical Center/Wilmot Cancer Institute - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2022-01-03 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT04981821 shows while recruiting
NCT04981821 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which GO-EXCAP Mobile App is the first listed.
NCT04981821 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04981821 about?
NCT04981821 is a clinical study titled "A Randomized Trial of a Mobile Health Exercise Intervention for Older Adults With Myeloid Neoplasms". This is a phase 2 randomized controlled trial (RCT) to assess the preliminary efficacy of the a mobile health exercise intervention (GO-EXCAP) versus a chemotherapy education control in 100 older patients with MN receiving outpatient chemotherapy on physical function and patient-reported outcomes (f...
What is the current status of trial NCT04981821?
This trial is currently recruiting. It is a NA study. The enrollment target is 170 participants. The study started on 2022-01-03. Estimated completion is 2026-12-31.
What conditions does trial NCT04981821 study?
This clinical trial studies the following conditions: Cancer, Myeloid Neoplasm.
What interventions are being tested in trial NCT04981821?
The interventions under investigation include: GO-EXCAP Mobile App (BEHAVIORAL), Behavioral Placebo Control (BEHAVIORAL).
Who is sponsoring clinical trial NCT04981821?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04981821 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04981821's enrollment target sits among peer trials
170 252nd of 615 higher than 362 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
BfedBwell Optimization Pilot
RECRUITING · NA
-
Legal Evaluation for Greater Access to Cancer Care (LEGAL-CARE)
RECRUITING · NA
-
Optimizing the AYA Survivors' Coping and Emotional Needs Toolkit
RECRUITING · NA
-
Comprehensive Connected Cancer Care (C4): Intervention Evaluation
RECRUITING · NA
-
Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI